Breakthrough Pill Doubles Survival for Pancreatic Cancer | Atlanta News

FDA just approved a groundbreaking pill for advanced pancreatic cancer—daraxonrasib, now called Rasonque—targeting the mutated protein behind 90% of these deadly tumors. In trials, patients lived nearly twice as long with far fewer side effects than chemo. Though pricey at $39,800 per month, it’s a lifeline for those out of options. This breakthrough could unlock treatments for other “undruggable” cancers too—and arrived six months early, signaling urgent hope in an otherwise grim fight. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a4994798c322daa0